Department of Urology, Eberhard-Karls-University Tuebingen, Germany.

The effectiveness of multikinase inhibitors in first- and second-line therapy of metastatic renal cell carcinoma (RCC) has been evaluated in various clinical studies. Initial results indicate an increased response rate and a prolonged progression-free survival compared with cytokine-containing therapeutic approaches. The new multitargeted kinase inhibitors sorafenib (Nexavar(R)/BAY 43-9006) and sunitinib (Sutent(R)/SUO 11248) interfere mainly with vascular endothelial growth factor and platelet-derived growth factor pathways. Recently, temsirolimus, a specific inhibitor of mammalian target of rapamycin, demonstrated activity in RCC patients with poor prognosis. This review discusses the effectiveness of the most frequently used substances for systemically progressive RCC in consideration of the currently available clinical data.

Written by
Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA.

Reference
Scand J Urol Nephrol. 2008 Jul 10:1-6. Epub ahead of print.

PubMed Abstract
PMID:18615363

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!